Diabetes Care, Vol 20, Issue 8 1279-1286, Copyright © 1997 by American Diabetes Association

ARTICLES

Metabolic efficacy of preprandial administration of Lys(B28), Pro(B29) human insulin analog in IDDM patients. A comparison with human regular insulin during a three-meal test period

MA Jacobs, ET Keulen, K Kanc, S Casteleijn, P Scheffer, W Deville and RJ Heine
Department of Endocrinology, Free University, Amsterdam, The Netherlands.

OBJECTIVE: The objective of this study was to compare the efficacy of the rapid-acting Lys(B28), Pro(B29) human insulin analog, insulin lispro, with currently available short-acting human insulin in a multiple injection therapy (MIT) regimen with respect to blood glucose and plasma insulin profiles and to serum metabolites (lactate, free fatty acids, glycerol, and beta-hydroxybutyrate) in 12 well-controlled type 1 diabetic subjects (8 male, HbA1c 6.8 +/- 0.9% [mean +/- SD]). RESEARCH DESIGN AND METHODS: After a run-in period of 4 weeks, patients were treated with either lispro at mealtime or human insulin 30 min before the meal for two periods of 4 weeks in a randomized open-label crossover study. Intermediate-acting insulin (NPH insulin) was given at bedtime. At the end of both study periods, metabolic profiles were assessed from 10:00 P.M. to 7:00 P.M. the next day. RESUlTS: During the treatment periods, glycemic control was stable during lispro but improved during human insulin (delta HbA1c lispro 0.1 +/- 0.48, NS; human insulin -0.41 +/- 0.34%, P < 0.05). Glucose excursions, as measured by the incremental AUC, during the day and for the 2-h postprandial periods, were lower, although not significantly, for lispro. Insulin profiles demonstrated a faster rise after administration of lispro as compared with human insulin, peaking at 61 +/- 11.9 and 111 +/- 48.1 min (P < 0.01). Glycerol levels showed a slight increase before lunch and dinner, suggestive of enhanced lipolytic activity and compatible with the lower insulin levels. CONCLUSIONS: Lispro insulin applied in an MIT regimen creates more physiologic insulin profiles and tends to lower the glycemic excursions during the day compared with short-acting insulin. The analog can be applied safely in an MIT regimen, with mealtime intervals up to 5 h.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. V. Edelman Optimizing Diabetes Treatment Using an Amylin Analogue The Diabetes Educator, January 1, 2008; 34(1_suppl): 4S - 10S. [Abstract] [Full Text] [PDF]

				D. G. Marrero, J. Crean, B. Zhang, T. Kellmeyer, M. Gloster, K. Herrmann, R. Rubin, N. Fineberg, and O. Kolterman Effect of Adjunctive Pramlintide Treatment on Treatment Satisfaction in Patients With Type 1 Diabetes Diabetes Care, February 1, 2007; 30(2): 210 - 216. [Abstract] [Full Text] [PDF]

				S. V. Edelman and L. Caballero Amylin Replacement Therapy in Patients With Type 1 Diabetes The Diabetes Educator, May 1, 2006; 32(Supplement_3): 119S - 127S. [Abstract] [Full Text] [PDF]

				D. F. Kruger, C. L. Martin, and C. E. Sadler New insights into glucose regulation. The Diabetes Educator, March 1, 2006; 32(2): 221 - 228. [Abstract] [Full Text] [PDF]

				J. Plank, A. Siebenhofer, A. Berghold, K. Jeitler, K. Horvath, P. Mrak, and T. R. Pieber Systematic Review and Meta-analysis of Short-Acting Insulin Analogues in Patients With Diabetes Mellitus Arch Intern Med, June 27, 2005; 165(12): 1337 - 1344. [Abstract] [Full Text] [PDF]

				R. Retnakaran, J. Hochman, J. H. DeVries, H. Hanaire-Broutin, R. J. Heine, V. Melki, and B. Zinman Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections: The impact of baseline A1c Diabetes Care, November 1, 2004; 27(11): 2590 - 2596. [Abstract] [Full Text] [PDF]

				S. L. Aronoff, K. Berkowitz, B. Shreiner, and L. Want Glucose Metabolism and Regulation: Beyond Insulin and Glucagon Diabetes Spectr, July 1, 2004; 17(3): 183 - 190. [Abstract] [Full Text] [PDF]

				I. W Gallen Review: Helping the athlete with type 1 diabetes The British Journal of Diabetes & Vascular Disease, March 1, 2004; 4(2): 87 - 92. [Abstract] [PDF]

				C. Weyer, A. Gottlieb, D. D. Kim, K. Lutz, S. Schwartz, M. Gutierrez, Y. Wang, J. A. Ruggles, O. G. Kolterman, and D. G. Maggs Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes: A dose-timing study Diabetes Care, November 1, 2003; 26(11): 3074 - 3079. [Abstract] [Full Text] [PDF]

				C. Homko, A. Deluzio, C. Jimenez, J. W. Kolaczynski, and G. Boden Comparison of Insulin Aspart and Lispro: Pharmacokinetic and metabolic effects Diabetes Care, July 1, 2003; 26(7): 2027 - 2031. [Abstract] [Full Text] [PDF]

				T. Lindstrom, C. A. Hedman, and H. J. Arnqvist Use of a Novel Double-Antibody Technique to Describe the Pharmacokinetics of Rapid-Acting Insulin Analogs Diabetes Care, June 1, 2002; 25(6): 1049 - 1054. [Abstract] [Full Text] [PDF]

				B. Bode, R. Weinstein, D. Bell, J. McGill, D. Nadeau, P. Raskin, J. Davidson, R. Henry, W.-C. Huang, and R. R. Reinhardt Comparison of Insulin Aspart With Buffered Regular Insulin and Insulin Lispro in Continuous Subcutaneous Insulin Infusion: A randomized study in type 1 diabetes Diabetes Care, March 1, 2002; 25(3): 439 - 444. [Abstract] [Full Text] [PDF]

				R. Rabasa-Lhoret, J. Bourque, F. Ducros, and J.-L. Chiasson Guidelines for Premeal Insulin Dose Reduction for Postprandial Exercise of Different Intensities and Durations in Type 1 Diabetic Subjects Treated Intensively With a Basal-Bolus Insulin Regimen (Ultralente-Lispro) Diabetes Care, April 1, 2001; 24(4): 625 - 630. [Abstract] [Full Text]